News & Insights

English adaptation · 23 October 2026 · Consortium launched 15 July 2026

DiPath is among the seven initial members of CellCarta’s Global Digital Pathology and AI Consortium, announced on 15 July 2026. The collaboration brings pathology AI developers into a shared network led by a global contract research laboratory, connecting image analysis with biomarker research and clinical development.

The consortium combines participating companies’ technologies with CellCarta’s laboratory infrastructure, pathologist-led workflows and regulatory experience. Its remit spans biomarker discovery, patient stratification, clinical trials and companion diagnostic development. The model is non-exclusive and open to different AI platforms, allowing sponsors to evaluate technologies against the needs of individual programs.

Sources: CellCarta announcement, 15 July 2026; DiPath coverage, 30 September 2026.

English adaptation · 23 October 2026 · Financing reported 28 July; Westlake coverage 20 August 2026

DiPath completed a Series C round of several hundred million renminbi, first reported in July 2026. Westlake University’s 20 August profile describes the investment as backing the company’s next stage of pathology AI development, including further work on DeepPathAI, upgrades to multi-omics analysis and international market expansion.

Founded by Westlake professor Lin Yang and incubated by the university’s Research Center for Industries of the Future, DiPath connects research in biomedical imaging with clinical and pharmaceutical applications. The funding will support development across both settings, with pathology images serving as a basis for more structured, quantitative analysis.

Sources: Westlake University, 20 August 2026; VCBeat, 28 July 2026.

English adaptation · 23 October 2026 · Event held 17–20 July 2026 in Shanghai

At the 2026 World Artificial Intelligence Conference in Shanghai, DiPath presented DeepPathAI alongside its connected digital pathology portfolio at the MetaX booth, H2-B401. The exhibition, held from 17 to 20 July, brought the company’s model development and laboratory workflows into the wider AI industry conversation.

The display connected slide scanning, intelligent microscopy, AI-assisted image analysis and pathology information management. Visitors could discuss how these components fit together in a department, from acquiring an image to organising cases and reviewing findings. The joint presentation also highlighted DiPath’s adaptation work with MetaX computing infrastructure as part of its continued development of pathology AI applications.

Adapted from DiPath’s company event report, reproduced by Pharmcube and VCBeat on 22 July 2026.

English adaptation · 23 October 2026 · Collaboration launched 26 June 2026 in Guangzhou

DiPath joined Astellas China and two other pathology AI companies in Guangzhou on 26 June 2026 to launch a collaboration focused on CLDN18.2 assessment in gastric cancer. The initiative explores how digital pathology and AI can support more consistent biomarker assessment alongside established pathology practice.

The partners aim to connect their experience in targeted therapies, image analysis and pathology workflows, with an emphasis on standardising interpretation. For DiPath, the collaboration brings DeepPathAI research and algorithm development into a defined biomarker setting. Its focus is the development of AI-assisted assessment methods and workflows, with the pathologist retaining responsibility for clinical interpretation.

Sources: collaboration announcement carried by Jiemian; participating partner Guangzhou LBP, 30 June 2026.

External clinical research · Study published 19 June 2026 · Perspective by DiPath

What the study brings together

HER2-LADDER, published in Signal Transduction and Targeted Therapy, combined pretreatment pathology images and clinical variables to study response to neoadjuvant dual HER2-targeted therapy in HER2-positive breast cancer.

H&E images

HoVer-Net analysed cells.

HER2 IHC images

A customized D-PathAI pipeline measured membrane staining intensity and completeness.

Research framework

Image measurements contributed to spatial analysis and response prediction.

The authors call for prospective validation and note potential selection bias in retrospective analyses, alongside variation in staining and scanning.

D-PathAI’s role was image analysis within a separate research framework. The study does not establish a treatment-selection function for the current product.

English news summary · 23 October 2026 · Summit held 10 May 2026

The second Digital and Intelligent Pathology Summit, DIPS 2026, took place at Northwest University’s Chang’an campus in Xi’an on 10 May. Its theme, “From DeepPathAI to DeepPathClaw,” framed a discussion about how foundation models and AI agents could contribute to pathology practice.

Lin Yang presented research on the next generation of pathology agents. Across the program, speakers addressed clinical validation, standardisation, disease-specific applications, virtual staining and image–text integration. The discussions connected algorithm development with the practical needs of pathologists, including quality control and interpretable workflows.

The summit was jointly hosted by Northwest University, Xijing Hospital and the Beijing Jingjian Pathology Development Foundation. Based on the host university’s report. Visit the conference website for the program.

On 6 January 2026, DiPath founder and Westlake University professor Lin Yang donated company equity to the university at a ceremony on its Yungu campus in Hangzhou. DiPath staff joined university representatives for the occasion.

In the university’s report, Yang linked the donation to his commitment to education and original research. He described the complementary roles of bringing research into practical medical workflows through a company and exploring foundational AI questions at a university, while supporting the next generation of curious, socially responsible innovators.

Sources: Westlake University, 7 January 2026.

English event recap · Event held 27 October 2025 · Reported 29 October 2025

DiPath presented its pathology AI software and digital slide scanners at the 2025 Zhejiang Service Trade Digital Healthcare Exhibition in Riyadh. Held on 27 October, the event brought together eight Zhejiang companies as part of a delegation organised by the provincial Department of Commerce.

Zhejiang Online reported that DiPath reached a cooperation agreement with a local medical agency and signed at the event. The visit opened discussions about bringing digital pathology technology to the region.

Adapted from Zhejiang Online, 29 October 2025, by reporter Chen Lei. The report does not name the agency or specify an implementation timetable. Hangzhou Daily’s April 2026 company profile also records DiPath’s participation.

English adaptation · 23 October 2026 · Launch session: 20 September 2025 · Press coverage: October 2025

SooPathAI was introduced in Suzhou on 20 September 2025 at the digital pathology and AI meeting marking the 70th anniversary of the Chinese Journal of Pathology. The model was developed and presented by the pathology department of the First Affiliated Hospital of Soochow University together with Westlake University.

The reported workflow connects slide screening, navigation to suspicious regions and interactive image analysis. Integration with the department’s information system brings image findings and clinical records into structured reports for pathologist review. DiPath was among the meeting’s supporting organizations listed in the program.

Sources: SooPathAI report, ifeng.com, 11 October 2025; Meeting program, 20 September 2025.

English adaptation · 23 October 2026 · Launch: 30 March 2025 · University report: 2 April 2025

DeepPathAI was introduced on 30 March 2025 at the first Digital and Intelligent Pathology Summit at Westlake University in Hangzhou. Developed by Lin Yang’s Artificial Intelligence and Biomedical Image Analysis Laboratory, the model was designed to work across microscope fields of view and whole-slide images.

The summit brought pathologists and AI researchers together to discuss how foundation models could fit into pathology practice. In its subsequent report, Westlake described plans for a deployment at Hangzhou First People’s Hospital, linking the model’s research development with clinical use.

Sources: Westlake University, 2 April 2025; DIPS 2025 archive.

English adaptation · 23 October 2026 · Takeda China announcement: 18 December 2024

DiPath was among the companies selected to work with Takeda China at the fourth TakedaSpark innovation challenge. In its 18 December 2024 announcement, Takeda reported that five projects from 47 submissions would advance to proof-of-concept work.

The selected portfolio explored digital approaches to screening, diagnosis and assessment across several therapeutic areas. The program gave participating teams a route to develop and evaluate their concepts with a biopharmaceutical partner; the work was at the proof-of-concept stage.

Sources: Takeda China announcement, PR Newswire, 18 December 2024.

English adaptation · 23 October 2026 · Agreement announced: 6 November 2023

DiPath and Takeda China signed a strategic cooperation agreement at CIIE in Shanghai on 6 November 2023. The announced collaboration focused on AI-assisted digital pathology for CD30-positive lymphoma.

The partners planned an integrated platform connecting pathology image analysis with digital services in the diagnostic workflow. DiPath was one of four companies signing digital-health cooperation agreements with Takeda China at the event.

Sources: Event announcement, ifeng.com, 6 November 2023; Shangguan News, 10 November 2023.

English adaptation · 23 October 2026 · Announced: 6 September 2023 · CACLP report: 7 September 2023

Roche Diagnostics China announced its collaboration with DiPath on 6 September 2023. The offering connected DiPath’s pathology AI algorithms with Roche’s VENTANA DP 200 and DP 600 whole-slide scanners, bringing scanning and image analysis into a shared workflow.

The announcement covered HER2, ER, PR, Ki-67 and PD-L1 assessment, with a focus on breast cancer and non-small-cell lung cancer. It also described plans to integrate the algorithms into Roche’s digital pathology open platform in China.

Sources: CACLP, 7 September 2023.

English adaptation · 23 October 2026 · Research announcement: 20 February 2023 · University report: 21 February 2023

The Third Affiliated Hospital of Sun Yat-sen University presented Sandy on 20 February 2023. The hospital developed and refined the chronic rhinosinusitis pathology system with DiPath and other research and technology partners, connecting clinical expertise with image analysis.

The project supports identification and counting of inflammatory cells in nasal-polyp tissue to assist disease-subtype assessment. It includes microscope-field analysis and a whole-slide cloud workflow. In a February 2025 review, the hospital reported wider use across partner hospitals, extending the collaboration beyond its original specialist setting.

Sources: Sun Yat-sen University / People’s Daily, 21 February 2023; Guangzhou Daily / New Flower City, 20 February 2023; Hospital progress review, 10 February 2025; 2023 clinical study describing the system.

English adaptation · 23 October 2026 · Partner announcement: 15 July 2022

×

MEDx Translational Medicine announced a development collaboration with DiPath on 15 July 2022, focused on software for the analysis of immunohistochemistry images.

The partnership brought MEDx’s pathology and companion-diagnostic capabilities together with DiPath’s image-analysis algorithms. Its stated focus included AI-assisted PD-L1 quantification, supporting pathologists as they assess staining and review results in the context of the assay.

Sources: MEDx announcement on its Sohu account, 15 July 2022; MEDx official company website.

English adaptation · 23 October 2026 · ZEISS company announcement: 8 June 2022 · Photograph: CIIE, November 2022

ZEISS announced a cervical cytology system developed with DiPath in June 2022. The collaboration combines ZEISS microscope imaging with DiPath’s cervical cytology AI module, supporting screening workflows in China.

The system acquires digital images and flags suspicious cells for review. A pathologist can select a candidate and return to the corresponding microscope field, keeping AI-assisted screening connected to direct visual inspection. Later that year, ZEISS highlighted the co-developed system at CIIE as part of its ZEISS+ local-innovation strategy.

Sources: ZEISS company announcement, 8 June 2022; ZEISS-authored release, Bioon, 9 June 2022; CIIE report, 36Kr via Sohu, 9 November 2022; ZEISS+ announcement coverage, 7 November 2022.

English adaptation · 23 October 2026 · Agreement: 23 April 2021 · Company report republished: 20 June 2021

DiPath and AstraZeneca China signed a strategic cooperation memorandum in Wuxi on 23 April 2021, during the Taihu Bay life-science conference. The agreement covered digital pathology and AI for oncology, with a focus on supporting pathology services in county-level hospitals.

The collaboration continued to develop. In August 2022, AstraZeneca’s own announcement identified DiPath as a partner in co-developing an AI-assisted HER2 assessment solution for breast cancer.

Sources: DiPath report republished by Surgi-plan, 20 June 2021; AstraZeneca China, 5 August 2022.